For example, valproic acid treatment in the SOD1 transgenic ALS mice only prevented motor neuron death, but failed to improve survival or motor performance (Rouaux et al., 2007), and similar results were observed in the clinical trial in humans (Piepers et al., 2009). The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.